Contents

Search

valganciclovir (Valcyte)

Indications: - cytomegalovirus (CMV) retinitis - CMV prophylaxis [5] Dosage: 1) 900 mg PO BID for 21 days (active CMV retinitis) 2) 900 mg QD maintenance 3) see ref [4] for calculation of pediatric dosage 4) maxmimum dose 900 mg BID [3,4] Adverse effects: - potential carcinogen & teratogen - do NOT handle broken tablets Laboratory: - valganciclovir in plasma Mechanism of action: metabolized to ganciclovir Notes: Manufacturer: Roche

Interactions

drug interactions

Related

ganciclovir; DHPG (Cytovene, Vitrasert, Zirgan)

General

antiviral agent

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 8(5):28 2001
  2. Department of Veterans Affairs, VA National Formulary - restricted to CMV retinitis
  3. FDA MedWatch Valcyte (valganciclovir hydrochloride) Label Change: Possible overdose in pediatric patients http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm225888.htm
  4. FDA Drug Safety Announceement FDA Drug Safety Communication: New dosing recommendations to prevent potential Valcyte (valganciclovir) overdose in pediatric transplant patients http://www.fda.gov/Drugs/DrugSafety/ucm225727.htm
  5. Deprecated Reference